Patent · US Active

Human cytomegalovirus comprising exogenous antigens

US10428118B2 · kind B2 · utility

4Cited by

14References

20Claims

0Family size

Assignee

Oregon Health & Science University · US

Inventors

Klaus Frueh · Portland, US
Scott Hansen · Portland, US
Jay Nelson · Lake Oswego, US
Louis Picker · Portland, US
Patrizia Caposio · Beaverton, US

Key dates

Filing date	Jul 16, 2015
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Jul 16, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.